Factors determining anti-poliovirus type 3 antibodies among orally immunised Indian infants

File Description SizeFormat 
1-s2.0-S0264410X16307046-main.pdfPublished version456.82 kBAdobe PDFView/Open
Title: Factors determining anti-poliovirus type 3 antibodies among orally immunised Indian infants
Authors: Kaliappan, SP
Venugopal, S
Giri, S
Praharaj, I
Karthikeyan, AS
Babji, S
John, J
Muliyil, J
Grassly, N
Kang, G
Item Type: Journal Article
Abstract: Background Among the three poliovirus serotypes, the lowest responses after vaccination with trivalent oral polio vaccine (tOPV) are to serotype 3. Although improvements in routine immunisation and supplementary immunisation activities have greatly increased vaccine coverage, there are limited data on antibody prevalence in Indian infants. Methods Children aged 5–11 months with a history of not having received inactivated polio vaccine were screened for serum antibodies to poliovirus serotype 3 (PV3) by a micro-neutralisation assay according to a modified World Health Organization (WHO) protocol. Limited demographic information was collected to assess risk-factors for a lack of protective antibodies. Student’s t-test, logistic regression and multilevel logistic regression (MLR) model were used to estimate model parameters. Results Of 8454 children screened at a mean age of 8.3 (standard deviation [SD]-1.8) months, 88.1% (95% confidence interval (CI): 87.4–88.8) had protective antibodies to PV3. The number of tOPV doses received was the main determinant of seroprevalence; the maximum likelihood estimate yields a 37.7% (95% CI: 36.2–38.3) increase in seroprevalence per dose of tOPV. In multivariable logistic regression analysis increasing age, male sex, and urban residence were also independently associated with seropositivity (Odds Ratios (OR): 1.17 (95% CI: 1.12–1.23) per month of age, 1.27 (1.11–1.46) and 1.24 (1.05–1.45) respectively). Conclusion Seroprevalence of antibodies to PV3 is associated with age, gender and place of residence, in addition to the number of tOPV doses received. Ensuring high coverage and monitoring of response are essential as long as oral vaccines are used in polio eradication.
Issue Date: 24-Aug-2016
Date of Acceptance: 11-Aug-2016
URI: http://hdl.handle.net/10044/1/45296
DOI: https://dx.doi.org/10.1016/j.vaccine.2016.08.032
ISSN: 1873-2518
Publisher: Elsevier
Start Page: 4979
End Page: 4984
Journal / Book Title: Vaccine
Volume: 34
Issue: 41
Copyright Statement: © 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC-BY license (http://creativecommons.org/licenses/by/4.0/).
Sponsor/Funder: Medical Research Council (MRC)
Funder's Grant Number: MR/K010174/1B
Keywords: Science & Technology
Life Sciences & Biomedicine
Immunology
Medicine, Research & Experimental
Research & Experimental Medicine
Poliovirus
Seroprevalence
OPV
Infants
Immunogenicity
India
RANDOMIZED CONTROLLED-TRIAL
NEUTRALIZING ANTIBODIES
DEVELOPING-COUNTRIES
INTESTINAL IMMUNITY
VACCINE
CHILDREN
SEROPREVALENCE
AGE
IMMUNOGENICITY
MORTALITY
Virology
06 Biological Sciences
07 Agricultural And Veterinary Sciences
11 Medical And Health Sciences
Publication Status: Published
Open Access location: http://www.sciencedirect.com/science/article/pii/S0264410X16307046
Appears in Collections:Epidemiology, Public Health and Primary Care



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx